Tech Company Inital Public Offerings
Cortexyme IPO
Based in South San Francisco, Cortexyme is now a public company.
Transaction Overview
Company Name
Announced On
5/8/2019
Transaction Type
IPO
Amount
$74,800,000
Proceeds Purpose
We intend to use the net proceeds from this offering to fund our global Phase 2/3 GAIN clinical trial for COR388, and to support future clinical and preclinical activities, manufacturing and development of our library of compounds, as well as for working capital and general corporate purposes, which may include the costs of operating as a public company. We estimate that our current capital resources, along with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through 2021, including through the completion and the announcement of the top-line results of our Phase 2/3 GAIN trial. However, the net proceeds from this offering, together with our current cash, will not be sufficient for us to fund the development of COR388 through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of COR388.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
269 East Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Cortexyme (Nasdaq: CRTX) is developing treatments for Alzheimer's and other degenerative disorders.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 5/8/2019: HeyJobs venture capital transaction
Next: 5/8/2019: Repair Biotechnologies venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs